THE SHARE: Change: 0.00 SEK (-1.66%) / Price: 0.12 SEK / May 8, 2026, 6:00 pm (CEST)
  • Home
  • About
    • Introduction
    • Board of Directors
    • Management Team
    • Medical Advisors
    • Corporate Governance
    • Career
  • Technology
    • Physiological Targeting
    • Functional Nanoparticles
    • Publications
    • Patent
  • Portfolio
    • Pipeline
    • SpagoPix
    • Tumorad
  • Investor Relations
    • The Share
    • Analyst Coverage
    • Owners
    • Financial Reports
    • Financial Calendar
    • Equity research
    • Shareholder’s Personal Data
    • Share Issue
  • Media
    • Spago Nanomedical in media
    • Press Releases
    • Subscribe
    • Presentations
    • Events
    • Image Bank
  • Contact
    • Contact us

Press Releases

Year

Language

Category

  • 7 May, 2026
    Spago Nanomedical interim report January-March 2026 Regulatory
  • 6 May, 2026
    Spago Nanomedical’s phase I/IIa study Tumorad-01 meets a primary endpoint and provides further visible tumor uptake
  • 24 Mar, 2026
    Spago Nanomedical’s abstract on Tumorad® accepted for presentation at radiopharma conference
  • 17 Mar, 2026
    Spago Nanomedical continues recruitment in the phase I/IIa Tumorad-01 study following positive DMC recommendation
  • 10 Mar, 2026
    Spago Nanomedical strengthens CMC and supply capabilities to support next phase of Tumorad development

About Spago Nanomedical

Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of life-threatening and debilitating diseases.

Address

Spago Nanomedical AB
Scheelevägen 22
SE-223 63 Lund
Sweden

Contact

Phone: +46 46 811 88
LinkedIn

Member of:

Copyright © 2026 Spago Nanomedical AB. All Rights Reserved.
Design by Clavis Communications